Aerie Pharma (AERI) Tops Q2 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 4, 2022 4:01 PM EDTSecond Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021
Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022 Â
Aerie Expects to be Cash Flow Break Even During 2024
DURHAM, N.C.DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the second quarter ended June 30, 2022 and provides... More
